168 related articles for article (PubMed ID: 8328787)
1. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
Collins LA; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Jun; 37(6):1364-6. PubMed ID: 8328787
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Collins LA; Malanoski GJ; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Mar; 37(3):598-601. PubMed ID: 8460927
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.
Yamane N; Jones RN
Diagn Microbiol Infect Dis; 1991; 14(4):337-45. PubMed ID: 1889183
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.
Johnson CC; Taylor S; Pitsakis P; May P; Levison ME
Antimicrob Agents Chemother; 1992 Oct; 36(10):2342-5. PubMed ID: 1444316
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D
Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
Freeman C; Robinson A; Cooper B; Mazens-Sullivan M; Quintiliani R; Nightingale C
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):47-50. PubMed ID: 7789096
[TBL] [Abstract][Full Text] [Related]
13. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
14. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.
O'Hare MD; Ghosh G; Felmingham D; Grüneberg RN
J Antimicrob Chemother; 1990 Feb; 25(2):217-20. PubMed ID: 2139436
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.
de la Maza L; Ruoff KL; Ferraro MJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1383-4. PubMed ID: 2552910
[TBL] [Abstract][Full Text] [Related]
17. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
Nicas TI; Cole CT; Preston DA; Schabel AA; Nagarajan R
Antimicrob Agents Chemother; 1989 Sep; 33(9):1477-81. PubMed ID: 2817848
[TBL] [Abstract][Full Text] [Related]
18. Ramoplanin susceptibility testing criteria.
Barry AL; Pfaller MA; Fuchs PC
J Clin Microbiol; 1993 Jul; 31(7):1932-5. PubMed ID: 8349779
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(3):279-82. PubMed ID: 2507218
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model.
Whitman MS; Pitsakis PG; DeJesus E; Osborne AJ; Levison ME; Johnson CC
Antimicrob Agents Chemother; 1996 Jun; 40(6):1526-30. PubMed ID: 8726031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
